Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.50 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040357 | 0.93 | CCNC (0.60) | CCNCCDK8CDK19GPBAR1CYSLTR1 | |
| SCHEMBL29756381 | 0.93 | CCNC (0.60) | CCNCCDK8CDK19GPBAR1CYSLTR1 | |
| SCHEMBL7038611 | 0.91 | CCNC (0.49) | CCNCCDK8CDK19GPBAR1CYSLTR1 | |
| SCHEMBL28845060 | 0.84 | CCNC (0.40) | CCNCCDK8CDK19GPBAR1CYSLTR1 | |
| SCHEMBL7039481 | 0.80 | CCNC (0.65) | CCNCCDK8CDK19 | |
| SCHEMBL15104936 | 0.80 | CCNC (0.67) | CCNCCDK8CDK19 | |
| SCHEMBL7041310 | 0.77 | CCNC (0.72) | CCNCCDK8CDK19 | |
| SCHEMBL7038809 | 0.76 | CCNC (0.61) | CCNCCDK8CDK19 | |
| SCHEMBL15104812 | 0.75 | CCNC (0.57) | CCNCCDK8CDK19 | |
| SCHEMBL7241300 | 0.75 | CCNC (0.51) | CCNCCDK8CDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1293197-A1 | PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030185878-A1 | Process for producing phospholipid-containing drug | PHOSPHO1, PLTP, PTDSS2 | CCNC 3385/4885CDK8 2673/4885CDK19 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.